Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy
- PMID: 11755839
- DOI: 10.1016/s0002-9394(01)01322-8
Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy
Abstract
Purpose: To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART).
Methods: Prospective cohort study. Baseline (enrollment) data were compared between patients with newly diagnosed cytomegalovirus retinitis (incident cases) and those with previously diagnosed cytomegalovirus retinitis (prevalent cases).
Results: As of December 31, 2000, 45 incident and 200 prevalent cases had been enrolled. Among prevalent cases, the median time from cytomegalovirus retinitis diagnosis was 2.9 years. Incident cases were more likely than prevalent cases to be women (35.4% vs 15.3%, P =.001), African American (45.4% vs 20.4%, P =.002), and uninsured (29.6% vs 7.6%, P <.001). Incident cases were less likely than prevalent cases to be on HAART (51.2% vs 77.6%, P =.001) and to have had an immunologic response to HAART (increase in CD4(+) T-cell count to > 100 cells/microl) (12.2% vs 57.5%, P <.001). The median CD4(+) T-cell count at enrollment among incident cases was 17 cells/microl and among prevalent cases was 159 cells/microl (P <.001). Immune recovery uveitis had been diagnosed in 15.5% of the prevalent cases. Sixty-three percent of prevalent cases were not on anticytomegalovirus therapy.
Conclusions: There is a population of patients with previously diagnosed and longstanding cytomegalovirus retinitis who have experienced immune recovery as a consequence of HAART and are no longer receiving anticytomegalovirus therapy. There are demographic differences between incident and prevalent cases that may reflect the evolution of the AIDS epidemic and differences in utilization of health care services.
Similar articles
-
Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000).Am J Ophthalmol. 2008 Jan;145(1):12-22. doi: 10.1016/j.ajo.2007.09.040. Am J Ophthalmol. 2008. PMID: 18154751
-
Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment.Ophthalmology. 2007 Apr;114(4):780-6. doi: 10.1016/j.ophtha.2006.11.008. Epub 2007 Jan 25. Ophthalmology. 2007. PMID: 17258320
-
Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy.Am J Ophthalmol. 2000 Jul;130(1):49-56. doi: 10.1016/s0002-9394(00)00530-4. Am J Ophthalmol. 2000. PMID: 11004259
-
Immune recovery uveitis.Am J Ophthalmol. 2000 Jul;130(1):103-6. doi: 10.1016/s0002-9394(00)00537-7. Am J Ophthalmol. 2000. PMID: 11004267 Review. No abstract available.
-
Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.Herpes. 2007 Dec;14(3):66-71. Herpes. 2007. PMID: 18371289 Review.
Cited by
-
Case Report: Giant Oral Ulcers Attributed to Cytomegalovirus Infection in a Patient with AIDS.Am J Trop Med Hyg. 2023 Oct 16;109(6):1274-1276. doi: 10.4269/ajtmh.22-0775. Print 2023 Dec 6. Am J Trop Med Hyg. 2023. PMID: 37972321
-
Cytomegalovirus Esophagitis in an Immunocompromised Patient.Cureus. 2023 Sep 20;15(9):e45634. doi: 10.7759/cureus.45634. eCollection 2023 Sep. Cureus. 2023. PMID: 37868477 Free PMC article.
-
Timing of antiretroviral therapy for HIV-infected patients with cytomegalovirus retinitis: study protocol of a multi-center prospective randomized controlled trial.Trials. 2021 Mar 18;22(1):218. doi: 10.1186/s13063-021-05159-y. Trials. 2021. PMID: 33736696 Free PMC article.
-
Management of Advanced HIV Disease.Infect Dis Clin North Am. 2019 Sep;33(3):743-767. doi: 10.1016/j.idc.2019.05.005. Epub 2019 Jun 27. Infect Dis Clin North Am. 2019. PMID: 31255383 Free PMC article. Review.
-
Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS.Invest Ophthalmol Vis Sci. 2019 May 1;60(6):1853-1862. doi: 10.1167/iovs.18-26517. Invest Ophthalmol Vis Sci. 2019. PMID: 31042791 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials